TPX-4589, formerly LM-302, is an antibody-drug conjugate (ADC) currently being evaluated in a Phase 1 clinical trial of patients with Claudin18.2-positive advanced solid tumors. Claudin18.2 is a protein expressed in many gastrointestinal cancers, including gastric and GEJ adenocarcinoma, pancreatic carcinoma, biliary tract carcinoma, colorectal carcinoma and ovarian carcinoma.

Designed to be Different.

TPX-4589 is an ADC that targets Claudin18.2 (CLDN18.2), which is a tight junction molecule involved in the regulation of permeability, barrier function, and polarity of epithelial layers. In healthy tissue its expression is restricted to tight junctions of gastric mucosal cells, and it is inaccessible to intravenous antibodies. In the cancer setting, CLDN18.2 can become exposed on the cell surface which allows it to be targeted.

There are currently no approved therapies targeting CLDN18.2.

TPX-4589 Development Designations

TPX-4589 was granted two Orphan Drug designations in pancreatic cancer and gastric cancer, including cancer of the gastroesophageal junction, by the U.S. Food and Drug Administration.

Turning Point Therapeutics is now a
Bristol Myers Squibb company

Select OK for information about Turning Point Therapeutics.

Select BMS to learn more about Bristol Myers Squibb